Download Neodyne Biosciences Announces Issuance of Additional US Patents

 Neodyne Biosciences Announces Issuance of Additional U.S. Patents for the
Treatment or Prevention of Scars and/or Keloids
Menlo Park, CA – June 07, 2013 - - Neodyne Biosciences, a medical device company focused on the
development and commercialization of innovative tissue repair devices to promote healing and minimize
scar formation, today announced the issuance of two U.S. Patents, including: U.S. Patent No. 8,389,791
entitled “Treatment Devices and Methods with Extending Elements” to Leland Stanford Junior University;
and U.S. Patent No. 8,395,011 entitled “Segmented Skin Treatment Systems and Methods” to Neodyne
Biosciences. Neodyne Biosciences owns or has an exclusive license to these issued patents.
The addition of these two patents further supports the company’s first product, embrace™ Advanced Scar
Therapy, which has 510(K) clearance from the US Food and Drug Administration (FDA). Embrace
Advanced Scar Therapy is an elastomeric dressing that is designed to off-load the tension of healing skin –
the treatment is known as mechanomodulation therapy.
“These issuances mark the 5th and 6th issued U.S. patents within our portfolio, further strengthening our
intellectual property position within mechanomodulation therapy for the treatment of post-surgical scarring”,
said Bill Beasley, President of Neodyne Biosciences. “While this promising technology can address the 80
million major surgical procedures that are performed annually, Neodyne Bioscience has chosen to focus on
the aesthetic marketplace first. It is a natural fit for patients who want to minimize the appearance of scars
after their cosmetic procedures like abdominoplasty.” About Neodyne Biosciences, Inc.
Neodyne Biosciences (www.neodynebio.com) is an evidence-based company developing and
commercializing innovative tissue repair devices to minimize scar formation, restoring both function and
aesthetic appearance. The company has developed stress-shielding devices capable of controlling the
mechanical wound environment to ameliorate post-surgical scarring. Although the etiology remains
unclear, mechanical forces such as surrounding skin tension and body movement have been
demonstrated to increase fibrosis and scar formation. It is estimated that approximately 80 million major
surgical procedures are performed in the United States each year and 230 million performed worldwide.
Patient frustration with post-surgical scarring spans a variety of procedures with many seeking means of
prevention and treatment.
Embrace Advanced Scar Therapy has received 510(K) clearance from the US Food and Drug
Administration and represents the company’s first commercially available product. It is currently under
limited distribution and available to Plastic Surgeons in select areas within the United States. For more
information on embrace Advanced Scar Therapy or to find a provider visit www.embracescartherapy.com .
Investor Relations Contacts:
Bill Beasley
President/COO
[email protected]
1-650-543-7127
2